GET DAILY SIGNALSC4 Therapeutics (CCCC): Is a Move Toward the $13 Target Feasible?
Key Takeaways
- The $13 central target represents the arithmetic mean of eight verified analyst price targets, rounding up from $12.63, with the individual estimates ranging from $7 to $30.
- From a recent price near $3.10, reaching $13 would mean a gain of roughly 320%, a substantial move under any circumstances.
- All current ratings on the stock are Buy, Overweight, or Outperform, yet the targets differ widely because the outcome depends heavily on binary clinical-trial results.
- The bull case centers on cemsidomide, the lead oral protein degrader, and upcoming trial readouts rather than existing revenue or earnings.
- The main risks include clinical setbacks, ongoing cash burn, and potential future dilution for shareholders.
- For additional detail on Major News, Today's Price Move, a full Forecast, and upcoming Earnings, visit the dedicated C4 Therapeutics pages.
- Explore Trending AI Robots to see AI-driven strategies monitoring stocks like CCCC.
Analyst Price Targets and the Consensus Picture
Because C4 Therapeutics remains pre-profit and its value hinges on pipeline milestones, analyst price targets show considerable variation. Looking at eight current, attributed targets produces a spread from $7 to $30. On the lower side, CCCC has $7 targets from Barclays and Guggenheim. Mid-range figures include $10 from J.P. Morgan and Wells Fargo, $11 from Lake Street, and $12 from Evercore ISI. Jefferies carries a $14 target, while Brookline Capital stands out at $30, raised earlier on optimism around the Phase 2 MOMENTUM trial. The arithmetic mean of these eight targets comes to roughly $12.63, which rounds to the $13 central target referenced here. This figure is simply an average of the individual forecasts, not an official consensus, and the broad range highlights the level of uncertainty around the company's ultimate valuation.
Current Market Position and the Path Forward
With shares trading near $3.10, a move to $13 would imply upside of about 320%. The 52-week range of roughly $1.69 to $5.17 illustrates the volatility seen so far. C4 Therapeutics posted revenue of approximately $6.6 million and a GAAP net loss of about $23.6 million in the June 2026 quarter, while holding roughly $300 million in cash that management expects will fund operations into late 2028. Without a meaningful earnings base to value at present, the route to $13 rests on clinical data that can de-risk the pipeline and broaden the perceived market opportunity for cemsidomide. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Factors That Could Support Higher Prices
Several confirmed elements back the constructive stance from analysts. Cemsidomide, an oral degrader aimed at IKZF1/3, is progressing in multiple myeloma through the Phase 2 MOMENTUM trial and a Phase 1b combination study with Pfizer's elranatamab under a collaboration announced in late 2025. A $125 million underwritten offering completed in October 2025 bolstered the balance sheet and drew interest from specialist life-science investors. Analysts have highlighted cemsidomide's differentiated safety and tolerability profile on multiple occasions, and the consensus rating stays uniformly positive with no Sell or Hold ratings in recent coverage.
Risks That Could Keep the Target Out of Reach
The primary risk is clinical in nature: if cemsidomide or other pipeline assets such as CFT8919 fail to demonstrate strong efficacy or safety, the rationale supporting the higher targets would weaken significantly. The company continues to report losses, revenue remains modest and is projected to decline in the near term, and additional capital raises could dilute existing shareholders. The unusually wide analyst range from $7 to $30 captures the reality that one negative readout could reset expectations sharply, while the stock has also tended to pull back after notable rallies.
Technical Levels and Market Structure
From a technical perspective, the shares are currently trading in the lower half of their 52-week range of approximately $1.69 to $5.17. The $5 area stands out as a key resistance level, coinciding with prior highs, and a sustained move above it would be needed before the stock could realistically approach the $13 zone. On the downside, support has developed near the $2-to-$3 area where buyers have stepped in repeatedly over the past year. The $13 target itself remains a distant psychological and technical milestone well above the stock's longer-term structure.
Time Horizon and Items to Monitor
Analyst price targets generally reflect an approximate 12-month horizon, although individual firms may apply different assumptions. For CCCC, the key catalysts are clinical rather than quarterly. Investors should track cemsidomide data from the MOMENTUM trial and the Phase 1b elranatamab combination study, any updates on CFT8919, the company's cash position and financing activity, and any analyst target revisions that follow data readouts. Quarterly earnings and guidance play a secondary role to the clinical calendar.
Incorporating AI Tools in My Research
I regularly turn to Tickeron's AI Daily Buy/Sell Signals when evaluating names like this one. The platform applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. For a volatile, news-driven stock such as C4 Therapeutics, these signals can help surface opportunities and track trend changes more efficiently alongside my own fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CCCC's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CCCC turned positive on October 19, 2026. Looking at past instances where CCCC's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CCCC's RSI Indicator exited the oversold zone, 30 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CCCC as a result. In 69 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +13.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCCC advanced for three days, in 194 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CCCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
CCCC moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CCCC moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CCCC entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.542) is normal, around the industry mean (3.482). P/E Ratio (-3.407) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (10.989) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. CCCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement